PARK HA BIOLOGICAL TECHNOLOG (PHH) Fundamental Analysis & Valuation
NASDAQ:PHH • KYG6925R1020
Current stock price
0.385 USD
0 (-0.08%)
At close:
0.4112 USD
+0.03 (+6.81%)
After Hours:
This PHH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PHH Profitability Analysis
1.1 Basic Checks
- In the past year PHH has reported negative net income.
- In the past year PHH had a positive cash flow from operations.
1.2 Ratios
- With a Return On Assets value of -331.89%, PHH is not doing good in the industry: 97.54% of the companies in the same industry are doing better.
- PHH has a Return On Equity of -455.43%. This is in the lower half of the industry: PHH underperforms 79.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -331.89% | ||
| ROE | -455.43% | ||
| ROIC | N/A |
ROA(3y)20.25%
ROA(5y)N/A
ROE(3y)81.07%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 92.99%, PHH belongs to the top of the industry, outperforming 97.54% of the companies in the same industry.
- PHH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. PHH Health Analysis
2.1 Basic Checks
- PHH does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, PHH has less shares outstanding
- PHH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- PHH has an Altman-Z score of 21.30. This indicates that PHH is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of PHH (21.30) is better than 100.00% of its industry peers.
- There is no outstanding debt for PHH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 21.3 |
ROIC/WACCN/A
WACC8.04%
2.3 Liquidity
- PHH has a Current Ratio of 3.68. This indicates that PHH is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 3.68, PHH belongs to the best of the industry, outperforming 92.62% of the companies in the same industry.
- PHH has a Quick Ratio of 3.63. This indicates that PHH is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.63, PHH belongs to the top of the industry, outperforming 96.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.68 | ||
| Quick Ratio | 3.63 |
3. PHH Growth Analysis
3.1 Past
- The earnings per share for PHH have decreased strongly by -2189.24% in the last year.
- PHH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.33%.
EPS 1Y (TTM)-2189.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38931.58%
Revenue 1Y (TTM)9.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.29%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. PHH Valuation Analysis
4.1 Price/Earnings Ratio
- PHH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- PHH's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 85.27 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. PHH Dividend Analysis
5.1 Amount
- No dividends for PHH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PHH Fundamentals: All Metrics, Ratios and Statistics
0.385
0 (-0.08%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap13.04M
Revenue(TTM)3.62M
Net Income(TTM)-19.36M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 25.64 | ||
| P/FCF | 85.27 | ||
| P/OCF | 79.05 | ||
| P/B | 21.85 | ||
| P/tB | 21.88 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY1.17%
OCF(TTM)0
OCFY1.26%
SpS0.02
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -331.89% | ||
| ROE | -455.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.99% | ||
| FCFM | 30.07% |
ROA(3y)20.25%
ROA(5y)N/A
ROE(3y)81.07%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)99.2%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 318.59% | ||
| Cap/Sales | 2.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.68 | ||
| Quick Ratio | 3.63 | ||
| Altman-Z | 21.3 |
F-Score5
WACC8.04%
ROIC/WACCN/A
Cap/Depr(3y)176.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.71%
Cap/Sales(5y)N/A
Profit Quality(3y)314.24%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2189.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38931.58%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1586.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y742.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y659.29%
OCF growth 3YN/A
OCF growth 5YN/A
PARK HA BIOLOGICAL TECHNOLOG / PHH Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for PARK HA BIOLOGICAL TECHNOLOG?
ChartMill assigns a fundamental rating of 3 / 10 to PHH.
What is the valuation status of PARK HA BIOLOGICAL TECHNOLOG (PHH) stock?
ChartMill assigns a valuation rating of 1 / 10 to PARK HA BIOLOGICAL TECHNOLOG (PHH). This can be considered as Overvalued.
How profitable is PARK HA BIOLOGICAL TECHNOLOG (PHH) stock?
PARK HA BIOLOGICAL TECHNOLOG (PHH) has a profitability rating of 1 / 10.